Proxygen

Genentech is to collaborate with Orionis Biosciences to discover and develop new ‘molecular glue’ medicines, a field which is already attracting much big pharma investment. The biotech will receive

Targeted protein degradation (TPD) is becoming a popular choice for Korean pharma firms looking for new drug modalities and growth engines. They are making diverse moves, largely seeking R&D collabora

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. JCR Signs Deal With Sumitomo On Izcargo

Protein-degradation specialist BioTheryX, Inc. has landed its first partnership, unveiling an alliance with Incyte Corporation on 5 April under which it will deploy its PRODEGY platform technology